Spear Bio
Ultra-Sensitive Biomarker Detection
Boston, United States · Founded 2021 · $45.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- spear.bio
- Total Funding
- $45.0M
- Last Round
- $45.0M Series AJul 2024
- Rounds
- 3
About
Spear Bio develops ultra-sensitive immunoassay kits and services based on its patented SPEAR (Successive Proximity Extension Amplification Reaction) technology. The wash-free, homogeneous platform detects protein biomarkers at attomolar concentrations using 1 µL or less of sample and a standard qPCR workflow, enabling research in neurological diseases including Alzheimer's, TBI, multiple sclerosis, and ALS.
Summary
Spear Bio is a Biotech company based in Boston, United States, founded in 2021. It has raised $45.0M in total across 3 rounds, most recently a $45.0M Series A round in Jul 2024. Investors include Maverick Ventures, CDH Investments and Foresite Capital.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...